// App-Quantinova.ai

PO1021 : Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs

Researchers

Presenter

  • Cherney David

Principal Investigators

  • Hadjadj Samy

  • Idorn Thomas

  • Mosenzon Ofri

  • Pilemann-Lyberg Sascha

  • Perkovic Vlado

  • Tuttle KatherineR

  • Rasmussen Soren

  • Bain StephenC

Medical Centers

  • Toronto General Hospital Toronto Ontario Canada

  • L'institut du thorax INSERM CNRS University of Nantes CHU Nantes Nantes France

  • Novo NordiskA/S, Soborg, Denmark

  • The George Institute for Global Health, Sydney, NewSouth Wales, Australia

  • Providence Medical Research Center Providence Health Care Spokane Washington United States

  • Swansea University Medical School Swansea Univeristy Swansea United Kingdom

Locations

  • Canada

  • France

  • Denmark

  • Israel

  • Australia

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Renal insufficiency

Biomarkers

  • Hemoglobin A1c

Drug/Treatment

  • Semaglutide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved